Q&A: Antibiotic resistance: What more do we know and what more can we do?

BMC Biology

Volumn 11, Issue , 2013, Pages

  Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECT; HUMAN; INTERVIEW;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 84877912627     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/1741-7007-11-51     Document Type: Article

References (14)

1. Centres for Disease Control and Prevention [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6209a3.htm?s_cid=mm6209a3_w].
2. Patel G, Bonomo RA. " Stormy waters ahead" : global emergence of carbapenemases. Front Microbiol 2013, 4:48. 3596785, 23504089.
3. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011, 11:355-362. 10.1016/S1473-3099(11)70059-7, 21478057.
4. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013, 309:163-170. 10.1001/jama.2012.176575, 23299608.
5. Klein EY, Sun L, Smith DL, Laxminarayan R. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study. Am J Epidemiol 2013, 177:666-674. 10.1093/aje/kws273, 23449778.
6. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012, 205:S228-S240. 10.1093/infdis/jir858, 22476720.
7. Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston MD, Barton HA, Wright GD. Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 2012, 7:e34953. 10.1371/journal.pone.0034953, 3324550, 22509370.
8. D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R, Golding GB, Poinar HN, Wright GD. Antibiotic resitance is ancient. Nature 2011, 477:457-461. 10.1038/nature10388, 21881561.
9. Forsberg KJ, Reyes A, Wang B, Selleck EM, Sommer MO, Dantas G. The shared antibiotic resistome of soil bacteria and human pathogens. Science 2012, 337:1107-1111. 10.1126/science.1220761, 22936781.
10. Cooper MA, Shlaes D. Fix the antibiotics pipeline. Nature 2011, 472:32. 10.1038/472032a, 21475175.
11. Farha MA, Leung A, Sewell EW, D'Elia MA, Allison SE, Ejim L, Pereira PM, Pinho MG, Wright GD, Brown ED. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to beta-lactams. ACS Chem Biol 2012, 8:226-233. 3552485, 23062620.
12. Kalan L, Wright GD. Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Rev Mol Med 2011, 13:e5.
13. PEW Trust Fact Sheet on the GAIN Act of 2011 [http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Fact_Sheets/Antibiotics_and_Innovation/Antibiotics_GAIN_FactSheet.pdf].
14. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, Lancaster C, Jackson J. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013, 13:269-275. 10.1016/S1473-3099(12)70293-1, 23332713.